vTv Therapeutics (VTVT) Cash & Equivalents (2014 - 2026)

vTv Therapeutics has disclosed Cash & Equivalents across 13 years of filings, most recently posting $86.6 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 234.25% year-over-year to $86.6 million; the TTM figure through Jun 2026 stood at $86.6 million (up 234.25% YoY), while the FY2025 annual figure was $88.9 million, up 142.02% from the prior year.
• Cash & Equivalents came in at $86.6 million for Q2 2026 at vTv Therapeutics, down from $98.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $98.5 million in Q3 2025 to a low of $8.2 million in Q3 2023.
• Average Cash & Equivalents over 5 years is $39.6 million, with a median of $28.5 million recorded in 2025.
• Year-over-year, Cash & Equivalents plunged 46.29% in 2023 and surged 404.98% in 2024.
• Over 5 years, Cash & Equivalents stood at $12.1 million in 2022, then slipped by 22.1% to $9.4 million in 2023, then jumped by 289.01% to $36.7 million in 2024, then jumped by 142.02% to $88.9 million in 2025, then dropped by 2.57% to $86.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $86.6 million in Q2 2026, $98.1 million in Q1 2026, and $88.9 million in Q4 2025.